Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + GemCis + Simvastatin in Advanced Biliary Tract Cancer
NCT07392541Phase 2Recruiting
- Sponsor
- Tongji Hospital
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab and simvastatin in biliary tract carcinoma (BTC), sponsored by Tongji Hospital. Primary endpoint: Objective Response Rate. Started Jan 2026; status: recruiting.
02
Drugs
adebrelimabsimvastatin
03
Conditions
biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT07392541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07392541.